How Long Does Eligard Stay in Your System?

Eligard’s physical presence in your body depends on which formulation you receive, with depot durations of one, three, or six months, but the drug’s effects on testosterone persist far beyond the point when the drug itself becomes undetectable. After a single subcutaneous injection of the one-month formulation, leuprolide remains measurable in the blood for roughly eight weeks; the six-month version maintains steady drug levels for about twenty-four weeks. The more consequential question for most people, though, is how long testosterone stays suppressed after the last dose, and that timeline is considerably less predictable.

How the Depot Releases Drug Over Time

Eligard uses a delivery system called Atrigel, which combines leuprolide acetate with a biodegradable polymer dissolved in a biocompatible solvent. When injected under the skin, the solvent diffuses away and the polymer solidifies into a small implant-like depot at the injection site. The drug then seeps out gradually as the polymer breaks down.¹ By adjusting the molecular weight of the polymer and the solvent concentration, manufacturers control whether that release lasts one month, three months, or six months.

The release is not perfectly smooth. Within the first few hours after injection, a relatively large burst of leuprolide escapes the depot. Lab studies using imaging techniques have shown that roughly 15% of the total drug load can leave the implant within the first three hours.² This initial burst is a well-known characteristic of PLGA-based depot formulations and is one of the reasons blood levels of leuprolide spike sharply in the first day or two before settling into a lower, steadier concentration.³

Blood Levels of the Drug Itself

If you are asking how long leuprolide is physically circulating in your blood, the answer follows a predictable pattern. For the six-month formulation, studies in prostate cancer patients show an initial peak in blood concentration followed by a rapid decline over the first week. After that sharp drop, mean leuprolide levels stay relatively constant through the end of the twenty-four-week dosing period.⁴ In other words, the drug does not build up to higher and higher concentrations; it plateaus at a low, sustained level and then tapers off as the depot runs out of drug to release.

A comparison between subcutaneous and intramuscular injection of leuprolide helps illustrate how the depot’s location affects how long the drug is detectable. In one study, leuprolide remained quantifiable in the blood for up to 56 days after a subcutaneous injection versus about 42 days after an intramuscular one.⁵ Eligard is specifically designed for subcutaneous use, which helps explain why its effects tend to be somewhat longer-lasting per dose compared to some intramuscular leuprolide products. The subcutaneous depot appears to release drug more slowly and over a longer window, keeping hormone suppression steadier.

When Testosterone Drops to Castrate Levels

For people using Eligard to treat prostate cancer, the question that matters most is not really about drug levels but about testosterone. The whole point of the injection is to suppress testosterone to what clinicians call castrate concentrations, generally defined as 50 ng/dL or below, with many aiming for the stricter threshold of 20 ng/dL or less.

Across four open-label studies covering the one-month, three-month, four-month, and six-month leuprolide formulations, the vast majority of patients reached testosterone levels at or below 20 ng/dL within six weeks of their first injection. The percentages ranged from 90% to 96% depending on the formulation. Once achieved, that suppression held remarkably well: between 90% and 97% of patients in all four studies maintained testosterone at or below 20 ng/dL from week six through at least week twenty-four.⁶ A real-world Belgian study found a similar pattern, with median testosterone dropping by about 94%, from 360 ng/dL at baseline to 20 ng/dL, and PSA falling by roughly 95%.⁷

So for the six-month formulation, the drug physically releases leuprolide for about six months, testosterone typically crashes by week four, and suppression holds through the dosing interval. That is the “normal operations” answer. The harder question is what happens when you stop.

The Testosterone Flare in the First Weeks

Before testosterone drops, it briefly goes in the wrong direction. Eligard is an LHRH agonist, meaning it stimulates the same receptor that the body’s natural hormone-releasing signal uses. When you first flood that receptor with a constant agonist, the pituitary gland initially responds by producing more luteinizing hormone, which temporarily drives testosterone up. This surge, known as a testosterone flare, typically occurs during the first one to two weeks after the initial injection.

For many men, the flare is clinically insignificant. But for those with advanced or metastatic disease, a temporary spike in testosterone can worsen symptoms, including bone pain, urinary obstruction, or spinal cord compression. For this reason, guidelines recommend that patients with advanced disease start an antiandrogen about a week before their first Eligard injection to block the effects of the flare.⁸ After the first dose, the continuous stimulation from leuprolide eventually desensitizes the pituitary receptors, LH production collapses, and testosterone follows it down. Subsequent injections produce a much smaller or negligible flare because the receptors are already desensitized.

The six-month depot formulation data confirm this: after the first dose, mean testosterone and LH both showed an initial increase above baseline and then dropped by week four. After the second dose at the six-month mark, the increases were negligible.⁴

How Long Effects Linger After the Last Injection

This is where the distinction between “the drug” and “the drug’s effects” becomes crucial. Leuprolide itself clears from your blood within weeks of the depot running out. But the hormonal consequences can persist for months or years, because prolonged LHRH agonist exposure does not just temporarily pause testosterone production; it can durably suppress the hypothalamic-pituitary-gonadal axis, and recovery depends on how long you were treated and a number of individual factors.

A study tracking 208 men after stopping androgen deprivation therapy found that 75% recovered testosterone to the castrate threshold of 0.5 ng/mL (50 ng/dL), but the median time to reach even that low bar was 11 months, with the middle half of patients taking between 7 and 13 months. Recovery to what the researchers defined as a normal testosterone level of 3.5 ng/mL (350 ng/dL) was far slower and far less common. Only about 19% of men reached that level during a median follow-up of over six years. Among the minority who did recover fully, the median time was 93 months, nearly eight years.⁹

A smaller, earlier study focusing on men who had been on LHRH analogues long-term told a broadly similar story. All patients eventually had some measurable testosterone recovery, but the mean time to the first detectable rise was about 13 months, with a range from 6 to 22 months. Among those who reached a normal level, it took an average of about 17.5 months, though this ranged up to 30 months for some individuals.¹⁰

Taken together, the evidence paints a consistent picture: most men will start to see some testosterone return within six months to a year of their last injection, but getting back to truly normal levels can take years, and a substantial proportion of men on long treatment courses never fully recover. The typical range cited in clinical practice for agonists like Eligard is 6 to 24 months to see meaningful recovery, though as the data above show, full normalization can take much longer.

Why Recovery Time Varies So Much

The enormous spread in recovery times is not random. Several factors predict whether testosterone comes back quickly or slowly, or at all.

Duration of treatment: The longer you were on Eligard or any other LHRH agonist, the longer recovery tends to take. Men treated for a few months have a much better chance of returning to normal testosterone within a year than men treated for two or three years. The pituitary’s ability to resume normal signaling degrades with prolonged suppression.
Age: Older men recover more slowly. Testosterone production naturally declines with age, and prolonged chemical suppression on top of age-related decline makes recovery less likely. The study that found a median recovery time of 93 months to normal levels was looking primarily at older prostate cancer patients, which partly explains the striking length of those numbers.
Baseline testosterone before treatment: Men who started with higher testosterone levels before their first injection tend to recover more fully. If baseline levels were already low, there is less function to recover.
Body composition and overall health: Obesity, diabetes, and other metabolic conditions can independently suppress testosterone and slow the recovery process after ADT.

Because recovery is so variable, clinicians generally recommend periodic testosterone monitoring after stopping Eligard rather than assuming any fixed timeline. Waiting and checking every few months is the standard approach; there is no reliable shortcut to predict exactly when any individual will recover.

What Subcutaneous Injection Means for Duration

Eligard is specifically formulated for subcutaneous injection, typically into the abdomen. This is not just a convenience preference; the route affects how the drug behaves. Compared to intramuscular delivery of similar leuprolide products, subcutaneous injection produces a lower initial peak concentration but a longer duration of measurable drug levels. In a direct comparison, the peak blood concentration after subcutaneous injection was lower than after intramuscular injection (about 19 versus 27 ng/mL), but the subcutaneous route maintained detectable leuprolide for about two weeks longer.⁵

The hormonal consequences tracked with that difference. In the same study, LH stayed suppressed below 1.0 IU/L through day 56 in the subcutaneous group, whereas it started rising by day 35 in the intramuscular group. By day 56, 13 out of 15 subcutaneous subjects still had castrate testosterone levels, compared with only 4 out of 15 in the intramuscular group.⁵ The practical takeaway is that Eligard’s subcutaneous design contributes to its reliability in maintaining suppression through the full dosing interval, and the injection site matters if you are comparing different leuprolide products.

Depot Integrity and What Can Go Wrong

Because Eligard relies on a solid depot forming at the injection site, anything that disrupts that depot can change how long the drug stays in your system. The depot needs to form properly to deliver its contents over the intended weeks or months. If the injection is too shallow and some of the material leaks back out, or if the depot forms in a highly vascular area and gets absorbed faster than expected, the effective duration can be shorter than labeled.

Injection technique matters more with Eligard than with a simple intramuscular shot. The Atrigel system requires mixing two syringes immediately before injection and delivering the product subcutaneously at the right depth. If the depot does not solidify correctly, the initial burst release can be exaggerated and the tail end of the dosing period can see testosterone starting to creep back up before the next scheduled injection. Clinicians sometimes catch this through routine PSA and testosterone monitoring when a patient’s levels begin rising earlier than expected.

There is no practical way to remove or reverse an Eligard depot once injected. Unlike an implant that can be surgically retrieved, the Atrigel depot is a semi-solid mass that biodegrades in place. If you experience side effects, you essentially have to wait for the depot to run its course. For the six-month formulation, that means committing to roughly half a year of drug exposure from a single injection, which is something worth discussing with your doctor before choosing between the available durations.

Monitoring While on Treatment and After Stopping

Most clinicians check both testosterone and PSA levels at regular intervals during Eligard therapy, typically around one month after the first injection, then at each subsequent dosing visit. The one-month check confirms that testosterone has dropped below the castrate threshold and catches the rare patient who does not respond. The Belgian practice study confirmed this approach works: by a median follow-up of about 132 days, both PSA and testosterone had fallen dramatically in the vast majority of patients.⁷

After stopping Eligard, monitoring becomes even more important because recovery is so unpredictable. The fact that some men take six months and others take years to recover any meaningful testosterone means that symptoms of low testosterone, including fatigue, loss of muscle mass, bone thinning, hot flashes, and mood changes, can persist well beyond the last injection. Bone density is a particular concern. One study tracking men after long-term LHRH analogue use noted changes in bone mineral density alongside slow testosterone recovery, highlighting the importance of bone health monitoring during and after treatment.¹⁰

Eligard in the Context of Gender-Affirming Care

While Eligard is approved and primarily prescribed for advanced prostate cancer, leuprolide formulations including Eligard are sometimes used off-label as puberty blockers in transgender adolescents or as part of hormone therapy in transgender women. The pharmacokinetics and testosterone suppression profiles are the same regardless of the indication. However, the recovery question looks different in these populations. A younger person with a healthy pituitary axis is generally expected to recover testosterone production faster than an older prostate cancer patient, though long-term suppression can still delay recovery by months. The limited data available in adolescents suggest that gonadal function typically resumes after stopping GnRH agonists, but the precise timeline depends on treatment duration and individual biology, much as it does in the cancer population.

People using Eligard in this context should be aware that the six-month formulation in particular represents a long commitment per injection, and that switching between formulations or discontinuing treatment requires planning around the depot’s release schedule rather than simply stopping a daily medication. There is no “off switch” once the injection is given.